UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume – What’s Next?

UCB SA (OTCMKTS:UCBJF) saw unusually-high trading volume on Thursday . Approximately 2,448 shares were traded during trading, an increase of 213% from the previous session’s volume of 781 shares.The stock last traded at $286.7250 and had previously closed at $289.84.

Wall Street Analysts Forecast Growth

UCBJF has been the topic of several research reports. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a report on Monday, February 16th. Wolfe Research initiated coverage on UCB in a report on Monday, February 23rd. They set an “outperform” rating on the stock. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy”.

UCB Price Performance

The firm’s fifty day moving average price is $294.20 and its 200 day moving average price is $296.36. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.